Oligonucleotide Theapeutics & Delivery 2016 | The Resurgence of Oligonucleotide Therapeutics

CHI recently interviewed Dr. Dmitry Samarsky, Senior Vice President of Technology and Global Business Development at OliX Pharmaceuticals, regarding the evolution of nucleic acid-based therapeutics; challenges within this space; recent advances in chemistry and delivery; and the greatest opportunities within this space over the next few years. Discussion questions include: 1 Given the obvious benefit of oligonucleotide therapies being able to dramatically expand target space, why haven’t they impacted the drug development landscape as much as Biologics or small Molecules? What challenges have been encountered within this field? 2 It seems as if there has be a resurgence of interest in the discovery and development of oligonucleotide therapeutics. Why do you think this is? What has changed over the past few years? 3 You are hosting a workshop during the upcoming Oligonucleotide Therapeutics and Delivery conference, providing an overview of oligonucleotide therapeutics from discovery to manufacturing. Can you tell us more about this workshop? Who should attend this? What can they expect to learn during this? 4 Oligonucleotide therapeutics seem to be evolving rapidly, but in your opinion, where do you see the greatest opportunities within this space over the next few years? For more information, visit http://www.HealthTech.com/Oligonucleotide/

There are no comments yet.

Please log in to write the first comment.